Company Data

NewAmsterdam Pharma Company N.V.

Ticker
NAMS
Current Price
$19 -0.63%
Market Cap
$1.8B
Price Target
Refer to Report
Volume
764.2K
52wk Range
$15.19 - $27.29
Advanced Market Data

Overview

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Inbox Intel from Channelchek.

Informed investors make more money. And itā€™s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy